| Literature DB >> 27176179 |
Sean Munoz1, Mabel Guzman-Rodriguez1, Jun Sun2, Yong-Guo Zhang2, Curtis Noordhof1, Shu-Mei He1, Emma Allen-Vercoe3, Erika C Claud4, Elaine O Petrof1.
Abstract
Using a murine Salmonella model of colitis, we recently reported that mice receiving a community of defined gut microbiota (MET-1) lost less weight, had reduced systemic inflammation and splenic S. typhimurium infection, and decreased neutrophil infiltration in the cecum, compared to vehicle controls. In addition, animals receiving MET-1 exhibited preserved tight junction protein expression (Zonula occludens-1, claudin-1), suggesting important effects on barrier function. In this addendum, we describe additional in vitro experiments examining effects of MET-1, as well as in vivo experiments demonstrating that MET-1 is protective in a DSS model of colitis after administration of antibiotics. Placed in the context of our findings and those of others, we discuss differences in our findings between the Salmonella colitis and DSS colitis models, provide speculation as to which bacteria may be important in the protective effects of MET-1, and discuss potential implications for other GI diseases such as IBD.Entities:
Keywords: DSS; epithelial barrier; microbial ecosystem therapeutic; microbiota; salmonella
Mesh:
Year: 2016 PMID: 27176179 PMCID: PMC4988458 DOI: 10.1080/19490976.2016.1188248
Source DB: PubMed Journal: Gut Microbes ISSN: 1949-0976